Keywords: Sarepta Thera, Eteplirsen, Duchenne muscular dystrophy, Ph IIb, AVI BioPharma

Sarepta's shares rocket on positive results with eteplirsen in Duchenne muscular dystrophy

Article | 25 July 2012

US RNA-based drug developer Sarepta Therapeutics (Nasdaq: SRPT) saw its shares leap 140% to $8.30 yesterday after the company, formerly known as ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Sarepta Therapeutics

AVI BioPharma

Go to company listing

Related Drugs

eteplirsen

Go to drug listing